

# **Neuroprotection**

## **Part I: Drugs & Markets**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**June 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist qualifications. He received graduate training in both Europe and USA and has held academic positions in several countries. He has been involved in biotechnology/pharmaceutical industry since 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK since 2000. After his retirement from neurosurgery, he is a consultant at Jain PharmaBiotech in Basel, Switzerland.

Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. As associate editor and contributing author of MedLink Neurology (San Diego, California), he is responsible for writing and yearly updating of 160 articles for continuing education of neurologists in an electronic encyclopedia of neurology. He has also written the Textbook of Gene Therapy, which was translated into Chinese, and a book on gene therapy companies published in 2000 by John Wiley & Sons. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer, 2008; 2<sup>nd</sup> ed 2014) and "Drug Delivery to the Central Nervous System", (Springer/Humana 2010). His recent books include "Handbook of Nanomedicine" (Springer/Humana 2008, Chinese edition by Peking University Press, 2011; 3<sup>rd</sup> ed Springer 2017), "Drug-induced Neurological Disorders, 3<sup>rd</sup> ed" (Hogrefe 2011), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2015, 2<sup>nd</sup> ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2<sup>nd</sup> ed 2018, in preparation), and "Applications of Biotechnology in Neurology" (Springer 2013). He has also edited "Applied Neurogenomics" (Springer 2015).

Prof. Jain has been involved in various neuroprotective strategies during his active neurosurgical career including use of hypothermia, hyperbaric oxygen and induced coma. He has a personal experience of methods of neuroprotection used in the care of patients with stroke and CNS trauma as well as during neurosurgical operations.

**June 2018 (first edition published in April 2000)  
Copyright © 2018 by:**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:       +4161-6924461  
Email:            info@pharmabiotech.ch  
Web site:         http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>28</b>
<b>1. Introduction .....</b>	<b>32</b>
<b>Definitions .....</b>	<b>32</b>
<b>Historical development of neuroprotection .....</b>	<b>32</b>
<b>Neurophysiological basis of neuroprotection .....</b>	<b>33</b>
Astrocytic glycogen-derived lactate as fuel for the brain.....	33
Gene expression in the human brain .....	33
Role of astrocytes in neuroprotection.....	34
Role of glymphatic system in neuroprotection.....	34
Role of sleep in neuroprotection.....	35
Role of cerebral metabolism in neuroprotection .....	35
Role of circadian genes in neuroprotection .....	35
Role of blood-brain barrier in neuroprotection.....	36
Role of the gut microbiota in development of integrity of the BBB .....	36
<b>Intrinsic neuroprotective factors .....</b>	<b>36</b>
Neuroprotective gene expression .....	38
<i>Upregulation of GADD34.....</i>	<i>38</i>
<i>Induction of NR4A proteins by CREB in neurons.....</i>	<i>38</i>
<i>Elevation PGC-1<math>\alpha</math> for neuroprotection in PD.....</i>	<i>38</i>
Neurotrophic factors.....	39
Intrinsic nonenzymatic antioxidants .....	39
Activation of transcription factor Nrf2 .....	39
Intrinsic neuroprotective proteins.....	40
<i><math>\alpha</math>B-crystallin.....</i>	<i>40</i>
<i>Excitatory amino acid transporters.....</i>	<i>40</i>
<i>Extracellular serine protease thrombin.....</i>	<i>40</i>
<i>Galanin.....</i>	<i>40</i>
<i>Neuroglobin.....</i>	<i>41</i>
<i>Nuclear factor I-A.....</i>	<i>41</i>
<i>Prion protein.....</i>	<i>42</i>
<i>Rai adaptor protein.....</i>	<i>42</i>
Stem cell factor .....	42
Role of the immune system in neuroprotection .....	42
Induction of DNA repair enzymes for neuroprotection.....	43
Microtubule-based neuroprotective response to axonal injury .....	44
<b>Pathomechanisms of CNS injury as basis for neuroprotection .....</b>	<b>44</b>
<b>Biomarkers of neurological disorders and neuroprotection.....</b>	<b>45</b>
CNS biomarker identification using proteomics .....	45
Brain imaging for detection of biomarkers.....	46
<b>Neuroprotection in neuroinflammation .....</b>	<b>46</b>
Biomarkers of neuroinflammation .....	46
<b>Role of neuroprotection in various neurological disorders .....</b>	<b>47</b>
<b>Neuroprotection and neuroregeneration.....</b>	<b>48</b>
<b>Acute versus chronic neuroprotection .....</b>	<b>48</b>
<b>Discovery and evaluation of neuroprotective agents .....</b>	<b>48</b>
Neuroprotective drug discovery .....	48
Discovery of CNS drugs that penetrate the blood-brain barrier .....	49
In vitro assays for the evaluation of neuroprotective agents .....	49
Oxidative injury model to test neuroprotective drugs.....	50
Apoptosis model for designing neuroprotective drugs .....	50
Transgenic mouse models of neurological disorders.....	50
Evaluating effects of neuroprotective drugs on living brain slices.....	51
Role of brain imaging in neuroprotective drug discovery and development .....	51
<i>Positron emission tomography.....</i>	<i>52</i>
<i>Role of single photon emission computed tomography.....</i>	<i>52</i>
<i>Functional CT scanning to evaluate cerebrovascular protection.....</i>	<i>52</i>
<i>Magnetic resonance imaging for the evaluation of neuroprotectives.....</i>	<i>53</i>
Application of nanotechnology to neuroprotection .....	53
<i>Nanoparticles as neuroprotective antioxidants.....</i>	<i>53</i>
<i>Cadmium telluride nanoparticles prevent A<math>\beta</math> fibril formation.....</i>	<i>54</i>
Evaluation criteria for potential neuroprotective agents.....	55
<b>2. Neuroprotective Agents .....</b>	<b>56</b>
<b>Classification of neuroprotective agents .....</b>	<b>56</b>
<b><math>\alpha</math>2 adrenoceptor agonists .....</b>	<b>60</b>
Dexmedetomidine .....	60

<b>Activated protein C</b> .....	<b>61</b>
<b>Activity-dependent neuroprotective protein</b> .....	<b>61</b>
Davunetide .....	61
<b>Adenosine analogs</b> .....	<b>61</b>
Propentofylline .....	62
<b>Antidepressants</b> .....	<b>62</b>
Antidepressant-induced neurogenesis.....	62
Neurogenesis induced by electroconvulsive therapy .....	63
Neuroprotective effect of selective serotonin reuptake inhibitors .....	63
<b>Antiepileptic drugs as neuroprotectives</b> .....	<b>65</b>
BIS-001.....	66
Levetiracetam .....	66
Phenytoin .....	66
Valproic acid.....	67
<b>Antiinflammatory agents</b> .....	<b>67</b>
Aspirin.....	67
Interleukin-1 antagonists.....	68
COX-2 inhibitors .....	68
<i>Nimesulide</i> .....	68
Gold microparticles as anti-neuroinflammatory agents.....	69
Minocycline .....	69
Prostaglandin receptor antagonists.....	70
<b>Anti-apoptosis agents</b> .....	<b>71</b>
Activated protein C .....	71
Calpain inhibitors.....	71
Caspase inhibitors.....	72
DNA binding drugs .....	72
Lithium.....	72
Melatonin.....	73
Olesoxime.....	73
Omega-3 fatty acids.....	73
<i>Docosahexaenoic acid</i> .....	73
Poly(ADP-ribose) polymerase inhibitors .....	74
Prevention of apoptosis by binding of proNGF to sortilin.....	75
<b>Antioxidants/free radical scavengers</b> .....	<b>75</b>
Free radical generation .....	75
Natural defenses against oxidative stress.....	75
Effects of oxidative damage .....	76
<i>Oxidative damage and aging</i> .....	76
<i>Neuronal damage by free radicals</i> .....	77
<i>Oxidative damage and neurodegenerative disorders</i> .....	77
Measures to control oxidative stress.....	77
<i>Categories of therapeutic antioxidants</i> .....	77
<i>Alpha-phenyl-tert-butylNitron</i> .....	78
<i>Coenzyme Q10</i> .....	78
<i>Dihydroergocryptine</i> .....	79
<i>Flavonoids</i> .....	79
<i>Mitochondria-targeted antioxidants</i> .....	80
<i>Neuroleptics as antioxidants</i> .....	80
<i>Nitrones</i> .....	80
<i>NRF2 for augmenting neuroprotection against oxidative stress</i> .....	81
Translation of antioxidant neuroprotection from preclinical to clinical.....	81
<b>Carbon monoxide and heme oxygenase</b> .....	<b>81</b>
<b>Cell transplants</b> .....	<b>82</b>
Cells secreting neuroprotective substances.....	82
Stem cells.....	82
Stem cell activation for neuroprotection/regeneration by glucocorticoids.....	83
Use of neural stem cells to construct the blood brain barrier.....	83
<b>Cytokines</b> .....	<b>83</b>
Erythropoietin .....	83
<i>Non-erythropoietic EPO variants and mimics</i> .....	85
Granulocyte colony-stimulating factor.....	85
<b>Delta-opioid receptor agonists</b> .....	<b>86</b>
Delta opioid peptide-induced hibernation for neuroprotection .....	86
<b>FK960</b> .....	<b>86</b>
<b>Gene therapy</b> .....	<b>87</b>
<b>Glucagon-like peptide</b> .....	<b>87</b>
<b>Glatiramer acetate</b> .....	<b>88</b>
<b>Glutamate antagonists</b> .....	<b>88</b>
Neuroprotection by scavenging blood glutamate .....	89
N-acylethanolamines for protection against glutamatergic excitotoxicity .....	90

Glutamate transporters.....	90
Glutamate transporter-mediated neuroprotective effect of drugs.....	90
Neuroprotection by targeting KAI subunit of kainate receptor .....	91
<b>Glycine-proline-glutamate analogs .....</b>	<b>91</b>
<b>Hydrogen sulfide.....</b>	<b>92</b>
Hibernation induced by hydrogen sulfide.....	92
<b>NMDA receptor ion channel complex.....</b>	<b>92</b>
NMDA receptor antagonists .....	94
<i>NMDA NR2B subunit receptor antagonists .....</i>	<i>94</i>
<i>Ifenprodil.....</i>	<i>94</i>
<i>Memantine as a neuroprotective agent .....</i>	<i>94</i>
<i>NAALADase inhibitors .....</i>	<i>95</i>
<i>Gacyclidine .....</i>	<i>95</i>
<i>N-alkylglycines .....</i>	<i>95</i>
AMPA receptor modulators .....	95
Metabotropic glutamate receptor modulators.....	96
Cannabinoids.....	96
Dexanabinol .....	97
<b>Glutathione.....</b>	<b>97</b>
<b>Heat shock proteins .....</b>	<b>98</b>
<b>Histone deacetylase inhibitors for neuroprotection .....</b>	<b>98</b>
<b>Hormones .....</b>	<b>98</b>
Estrogen and neuroprotection.....	98
<i>Neuroprotective effect of estrogen receptor ligands.....</i>	<i>99</i>
<i>Selective estrogen receptor modulators .....</i>	<i>100</i>
<i>Mitochondrial mechanisms of estrogen neuroprotection .....</i>	<i>100</i>
Insulin .....	100
<b>Ion Channel modulators .....</b>	<b>101</b>
Calcium channel blockers.....	101
<i>Ziconotide.....</i>	<i>102</i>
Na <sup>+</sup> channel blockers.....	102
Neuroprotective potassium channel inhibitors .....	102
<b>Kynurenine inhibitors .....</b>	<b>103</b>
<b>Leukocyte adhesion inhibitors .....</b>	<b>103</b>
<b>Modafinil.....</b>	<b>104</b>
<b>Neural regeneration protein .....</b>	<b>104</b>
<b>Neurite outgrowth-promoting agents .....</b>	<b>105</b>
Prostaglandin compounds .....	105
Monoclonal antibodies .....	105
<b>Neuroimmunophilins.....</b>	<b>105</b>
Cyclosporin-A .....	106
FK506 .....	106
Rapamycin.....	106
<b>Neurotrophic factors.....</b>	<b>107</b>
Activity-dependent neurotrophic factor .....	107
Bone morphogenetic proteins .....	107
Brain-derived neurotrophic factor.....	108
Ciliary neurotrophic factor .....	108
Fibroblast growth factors .....	109
Glial cell line-derived neurotrophic factor .....	109
Insulin-like growth factor.....	110
Nerve growth factor .....	110
Neurotrophins .....	111
Osteogenic protein-1 .....	111
Pigment epithelium-derived factor.....	111
Transforming growth factor-β1 .....	112
Vascular endothelial growth factor .....	112
Neurotrophic factor-related neuroprotective agents.....	112
<i>Amitriptyline as a TrkA and TrkB receptor agonist .....</i>	<i>112</i>
<i>Colivelin.....</i>	<i>113</i>
<i>Gambogic amide.....</i>	<i>113</i>
<i>Inosine .....</i>	<i>113</i>
<i>Meteorin .....</i>	<i>113</i>
<i>Oxygen-regulated protein 150 kD .....</i>	<i>114</i>
<i>Prosaptide.....</i>	<i>114</i>
<i>Siagoside.....</i>	<i>114</i>
<i>Small molecule activators of the Trk receptors.....</i>	<i>115</i>
<b>Nicotine and nicotinic receptor agonists .....</b>	<b>115</b>
<i>Neuroprotective effect of galantamine mediated via α7nAChRs .....</i>	<i>115</i>
<i>Galantamine-induced Aβ clearance via α7nAChRs .....</i>	<i>116</i>
<b>Nitric oxide-based neuroprotection .....</b>	<b>116</b>

Nitric oxide synthase inhibitors .....	117
Nitric oxide mimetics .....	117
Nitric oxide donating derivatives .....	117
<b>Nootropics .....</b>	<b>118</b>
<i>Piracetam</i> .....	118
<b>Nutraceuticals and naturally-derived compounds .....</b>	<b>119</b>
Cinnamon .....	119
Coffee .....	119
Creatine.....	120
Curcumin/curry .....	120
<i>Mechanism of neuroprotective effect of curcumin</i> .....	121
Flavonoids .....	121
Glyceryltriacetate.....	121
Green tea .....	121
Herbal preparations.....	122
<i>Flavonoid wogonin</i> .....	122
<i>Ginseng</i> .....	122
Nicotinamide .....	122
Punicalagin from pomegranate .....	123
Resveratrol .....	123
<b>Osmotic diuretics .....</b>	<b>124</b>
Mannitol .....	124
Osteopontin .....	124
<b>Oxygen therapeutics.....</b>	<b>125</b>
Oxygen carriers .....	125
Hemoglobin-based oxygen carriers.....	125
Perfluorocarbons as oxygen carriers .....	126
Hyperbaric oxygen therapy .....	127
<b>P7C3 compounds .....</b>	<b>127</b>
<b>Peptides.....</b>	<b>127</b>
C3-derived peptide for neuroprotection and neuroregeneration.....	127
Corticotropin-releasing hormone.....	128
Thyrotropin-releasing hormone.....	128
Vasoactive intestinal peptide .....	128
<b>Pharmacological preconditioning.....</b>	<b>129</b>
<b>PPARs as drug targets for neuroprotection.....</b>	<b>129</b>
<b>Proteins .....</b>	<b>130</b>
Amyloid precursor protein .....	130
Protein kinase C activators.....	130
<b>Riluzole.....</b>	<b>131</b>
<b>Role of RNA interference in neuroprotection .....</b>	<b>131</b>
Role of miRNA in neuroprotection.....	131
<b>Sigma receptor agonists as neuroprotective agents .....</b>	<b>132</b>
<b>SIRT group of proteins.....</b>	<b>132</b>
<b>Statins .....</b>	<b>133</b>
<b>Steroids .....</b>	<b>134</b>
Dehydroepiandrosterone.....	134
HF0220 .....	134
<b>Sulforaphane .....</b>	<b>135</b>
<b>Tauroursodeoxycholic acid .....</b>	<b>135</b>
<b>Tetanus toxin as a neuroprotective agent.....</b>	<b>135</b>
<b>Thrombolytic agents as neuroprotective agents .....</b>	<b>135</b>
<b>Uncoupling protein 2 .....</b>	<b>136</b>
<b>Vaccines as neuroprotectives .....</b>	<b>136</b>
<b>Vitamins as neuroprotective agents.....</b>	<b>136</b>
Vitamin B12 .....	137
Vitamin D .....	137
<b>Non-pharmacological approaches to neuroprotection.....</b>	<b>137</b>
Caloric restriction.....	138
Cerebral exercise .....	138
<i>Bilingualism for prevention of decline of mental function</i> .....	138
Electrical fields for improvement of cerebral function in neurodegeneration .....	138
Environmental enrichment .....	139
Hypothermia .....	139
<i>Limitations of hypothermia</i> .....	140
<i>Hypothermic neuroprotection in hypoxia-ischemia</i> .....	140
Ketogenic diet .....	141
Mediterranean diet.....	141
Nonpharmacological preconditioning for neuroprotection.....	141
Physical exercise.....	142
Suspended animation and neuroprotection.....	143

Transcranial magnetic stimulation .....	143
<b>3. Neuroprotection in Cerebrovascular Disease .....</b>	<b>146</b>
<b>Introduction .....</b>	<b>146</b>
<b>Pathophysiology of cerebral ischemia.....</b>	<b>147</b>
Calcium overload .....	147
Ion channel dysfunction in stroke.....	148
Role of oxygen free radicals in cerebral ischemia .....	148
Role of nitric oxide in cerebral ischemia .....	148
Glutamate as a biomarker of stroke .....	148
Cerebral edema in stroke.....	149
Gene expression in response to cerebral ischemia.....	149
Induction of heat shock proteins in stroke .....	149
Role of cytokines and adhesion molecules in stroke .....	150
<i>Tumor necrosis factor-<math>\alpha</math></i> .....	150
<i>Interleukin-1 and IL-6</i> .....	150
<i>Adhesion molecules</i> .....	150
DNA damage and repair in cerebral ischemia .....	150
Role of neurotrophic factors in stroke .....	151
<i>Problems requiring investigation of the role of NTFs in stroke</i> .....	151
Role of Poly(ADP-ribose) polymerase (PARP) gene .....	152
Role of protease-activated receptor 1 .....	152
<b>Reperfusion injury after cerebral ischemia .....</b>	<b>152</b>
<b>Neuroprotection according to zones in cerebral infarction.....</b>	<b>152</b>
Zone of ischemic infarction.....	152
Penumbra .....	153
<b>Current management of stroke .....</b>	<b>154</b>
Neuroprotection in stenosis of intracranial arteries .....	154
Neuroprotection in stroke with intracerebral hemorrhage .....	154
Neuroprotection in cerebrovascular malformations .....	155
<i>Arteriovenous malformations</i> .....	155
<i>Cavernous cerebrovascular malformations</i> .....	155
Neuroprotective strategies for ischemic stroke in patients with dementia .....	156
Neuroprotection in transient ischemic attacks.....	156
Secondary prevention of stroke .....	156
<b>Neuroprotective therapies for stroke .....</b>	<b>157</b>
<b>Pharmacologic neuroprotective agents for stroke.....</b>	<b>158</b>
$\alpha$ B-crystallin as a neuroprotectant in stroke .....	158
Acid-sensing ion channel blockers .....	158
AMPA receptor antagonists as neuroprotectives for stroke.....	158
<i>Zonampanel</i> .....	158
Antiapoptotic neuroprotectives .....	159
<i>NIM811</i> .....	159
<i>Creatine as neuroprotective in stroke</i> .....	159
<i>Lithium as a neuroprotective in stroke</i> .....	159
<i>TUDCA as a neuroprotective in stroke</i> .....	160
Antiepileptic drugs as neuroprotectives in stroke.....	160
<i>Tiagabine</i> .....	160
<i>Topiramate</i> .....	160
<i>Zonisamide</i> .....	161
Anti-HMGB1 monoclonal antibody .....	161
Antioxidant approaches .....	161
<i>Carnosine as a neuroprotective in stroke</i> .....	162
<i>Dehydroascorbic acid</i> .....	162
<i>Tocotrienols</i> .....	162
<i>Uric acid</i> .....	163
Antiglutamate compounds.....	163
<i>MRZ 2/576</i> .....	163
<i>L-Phenylalanine</i> .....	164
Arimocloamol for stroke .....	164
Cardiac glycosides as neuroprotectives in stroke .....	164
Clenbuterol .....	164
Coagulation inhibitors as neuroprotectives .....	165
<i>Heparin and enoxaparin</i> .....	165
<i>Warfarin vs dabigatran</i> .....	165
<i>Apixaban</i> .....	165
Cox-2 inhibitors for ischemic stroke.....	166
Curcumin as a neuroprotectant in stroke.....	166
Docosahexaenoic acid for ischemic stroke .....	166
Ephrin-A5 blockers.....	166
Estrogen for stroke .....	167

Extendin-4 .....	168
Flavones for neuroprotection in stroke .....	168
<i>Epicatechin</i> .....	168
<i>Isorhamnetin</i> .....	169
Granulocyte-macrophage colony-stimulating factor for cerebral ischemia .....	169
Hamartin induction by cerebral ischemia as a basis for neuroprotection .....	169
Histone deacetylase inhibitors for neuroprotection in stroke .....	170
Histamine H <sub>2</sub> -receptor modulation .....	170
Inosine for stroke .....	170
Insulin-like growth factor-I .....	171
Intravenous immunoglobulin as neuroprotective in stroke .....	171
Ischemic preconditioning for neuroprotection in stroke .....	171
Ketone bodies for neuroprotection in stroke .....	172
Magnesium .....	172
Mineralocorticoid receptor blockade for neuroprotection .....	172
miR-223 and neuroprotection in stroke .....	173
Multifunctional neuroprotective agents .....	173
NA-1 as neuroprotective against ischemic stroke .....	173
Nasal delivery of neuroprotective agents in stroke .....	174
Neuroserpin as a neuroprotective in stroke .....	174
N-2-mercaptopropionyl glycine .....	174
NeuroAid .....	174
Neurotrophic factors as neuroprotectives for stroke .....	175
<i>Brain-derived neurotrophic factor</i> .....	175
<i>Fibroblast growth factor</i> .....	175
<i>G-CSF</i> .....	176
<i>Glial cell line-derived neurotrophic factor</i> .....	176
<i>Insulin-like growth factor-1</i> .....	176
<i>Neuregulin-1</i> .....	176
NO-based strategies for neuroprotection in cerebral ischemia .....	177
NOX-4 inhibitors for neuroprotection in stroke .....	177
Omega-3 fatty acids for neuroprotection after cerebral ischemia-hypoxia .....	178
Pannexin channel blockers for neuroprotection in stroke .....	178
Perlecan domain V .....	178
Peroxisome proliferator-activated receptor- $\gamma$ agonists .....	178
PGE <sub>2</sub> EP2 receptor activation .....	179
Pioglitazone for reduction of stroke risk .....	179
Progesterone .....	179
Propofol as neuroprotective in stroke .....	179
Proteoglycan-degrading enzymes .....	180
Proteasome inhibitors .....	180
Statins for prevention and neuroprotection in stroke .....	180
Sildenafil .....	181
Src receptor blockade .....	181
Stroke vaccine .....	182
SUN N4057 .....	182
Thrombosis inhibitors .....	182
<i>Aspirin</i> .....	182
<i>Clopidogrel</i> .....	183
<i>Dipyridamole</i> .....	183
<i>Ticagrelor</i> .....	183
Vitamin E for neuroprotection in stroke .....	183
<b>Neuroprotection in ischemia-reperfusion injury .....</b>	<b>184</b>
Aminoguanidine .....	184
Dexmedetomidine .....	185
Methylene blue for neuroprotection in ischemia-reperfusion injury .....	185
Miscellaneous agents for neuroprotection in reperfusion injury .....	185
<b>Neuroprotection by treatment of cerebrovascular malformations .....</b>	<b>185</b>
<i>Arteriovenous malformations</i> .....	186
<i>Cerebral cavernous malformations</i> .....	186
<b>Prevention of hemorrhage following ischemic stroke .....</b>	<b>186</b>
<b>Non-pharmacological neuroprotective therapies for stroke .....</b>	<b>187</b>
Hypothermia for neuroprotection in acute stroke .....	187
Hyperbaric oxygen therapy for neuroprotection in acute stroke .....	187
Hypothermia combination with other neuroprotective strategies .....	188
Infrared laser therapy for ischemic stroke .....	189
Preconditioning for neuroprotection against cerebral ischemia .....	189
<i>Neuroprotection in ischemia/reperfusion injury</i> .....	190
<b>Neurosurgical procedures for stroke .....</b>	<b>191</b>
Neurosurgical procedures for neuroprotection in acute stroke .....	191
<i>Decompressive hemicraniectomy</i> .....	191



<i>Thrombectomy</i> .....	191
<i>Stenting</i> .....	192
<i>Multiple endovascular modalities</i> .....	192
Neurosurgical procedures for chronic cerebral ischemia .....	193
Neurostimulation of sphenopalatine ganglion.....	193
Stent versus surgery for asymptomatic carotid stenosis.....	194
<b>Neurorehabilitation in relation to neuroprotection in stroke.....</b>	<b>194</b>
Protective effect of physical activity on stroke in the elderly .....	194
<b>Biological therapies for stroke .....</b>	<b>194</b>
Cell therapy for stroke .....	194
<i>Stem cell transplant for stroke</i> .....	195
<i>Immortalized cell grafts for stroke</i> .....	195
<i>Stimulation of intrinsic stem cells for repair of brain in stroke</i> .....	196
Gene therapy for neuroprotection in cerebrovascular disease .....	196
Regulation of microRNAs for neuroprotection in cerebral ischemia.....	198
RNAi-based therapy for neuroprotection in stroke .....	198
Vaccines for neuroprotection in stroke .....	198
<b>Neuroprotective therapies for cerebral ischemia: clinical trials .....</b>	<b>199</b>
Albumin .....	200
Free radical scavengers .....	200
DP-b99 .....	201
Mildronate.....	201
Minocycline for neuroprotection in stroke .....	202
Perindopril .....	202
Failed clinical trials of neuroprotection in stroke.....	202
<i>Ancrod</i> .....	204
<i>Aptiganel</i> .....	204
<i>Cerovive</i> .....	204
<i>Citicoline</i> .....	205
<i>Desmoteplase</i> .....	206
<i>Erythropoietin as a neuroprotective in stroke</i> .....	207
<i>SPD 502</i> .....	207
<i>Tirilazad mesylate</i> .....	208
<i>Selfotel</i> .....	208
<i>Lubeluzole</i> .....	208
<i>Nalmefene</i> .....	208
<i>Gavestinel</i> .....	209
<i>Nimodipine</i> .....	209
<i>Sipatrigine</i> .....	209
<i>Causes of failure of stroke trials</i> .....	209
Measures for prevention of failures in stroke trials .....	211
Design of acute stroke trial to facilitate drug approval .....	212
<b>The ideal neuroprotective agent for stroke .....</b>	<b>213</b>
<b>Prevention of stroke .....</b>	<b>213</b>
<b>Future of neuroprotection in stroke .....</b>	<b>214</b>
<b>4. Neuroprotection in Traumatic Brain Injury .....</b>	<b>216</b>
<b>Introduction .....</b>	<b>216</b>
<b>Cerebral hypoxia/ischemia as a complication of trauma.....</b>	<b>216</b>
<b>Epidemiology of TBI.....</b>	<b>216</b>
TBI in the military .....	217
<b>Pathophysiology of TBI.....</b>	<b>217</b>
Immediate damage following TBI.....	218
Cerebral edema following TBI .....	218
Neurometabolic cascade after TBI .....	219
Delayed damage following TBI.....	219
Mechanism of axonal damage after TBI .....	220
Role of neuroinflammation in TBI .....	220
BBB damage after TBI .....	220
Molecular events following TBI.....	221
Chronic traumatic encephalopathy .....	221
Neurocognitive sequelae of TBI.....	223
Changes in neurotrophic factors following TBI .....	223
Changes in neurotransmitters following TBI.....	223
Proteomics of TBI .....	224
Genetic influences on outcome following TBI .....	224
<b>Management of TBI .....</b>	<b>225</b>
Management during acute phase of head injury .....	225
<i>Control of intracranial pressure and cerebral edema</i> .....	225
<i>Corticosteroids</i> .....	226
<i>Decompressive craniectomy</i> .....	227

<b>Neuroprotection in TBI .....</b>	<b>227</b>
Amantadine.....	228
Antioxidants .....	229
Barbiturates .....	229
$\beta$ - and $\gamma$ -secretase inhibitors .....	229
Beta blockers .....	229
Bradykinin B <sub>2</sub> antagonists .....	230
Cell cycle inhibitors for TBI.....	230
COX-2 inhibitors for neuroprotection in TBI .....	230
Cyclosporin for neuroprotection in TBI .....	231
Dexanabinol for TBI .....	231
Erythropoietin for neuroprotection in TBI .....	231
Gold implants for neuroprotection in focal TBI .....	232
Histone deacetylase inhibitors for neuroprotection in TBI .....	232
KN 38-7271 .....	232
Levosimendan .....	232
Magnesium sulfate .....	233
Minocycline for TBI.....	233
Multipotential neuroprotective agents for TBI .....	233
Nutritional approaches to neuroprotection in TBI.....	233
<i>Branched chain amino acids to ameliorate cognitive impairment in TBI.....</i>	<i>234</i>
<i>Creatine for neuroprotection in TBI .....</i>	<i>234</i>
<i>Nicotinamide for neuroprotection in TBI.....</i>	<i>235</i>
<i>Omega 3 fatty acids as neuroprotectives in TBI .....</i>	<i>235</i>
Neurotrophic factors for TBI .....	235
Neurosteroids as neuroprotective agents for TBI.....	236
NMDA receptor antagonists .....	237
<i>Neuroprotection in TBI against glutamate-induced excitotoxicity.....</i>	<i>237</i>
<i>NP-1 .....</i>	<i>238</i>
Nogo-A inhibitor .....	238
Oxygen carriers for TBI.....	238
Polyethylene glycol for neuroprotection in TBI .....	239
Propofol for neuroprotection in TBI.....	239
Rapamycin as neuroprotective in TBI.....	239
Simvastatin as neuroprotective in TBI .....	240
Thyrotropin-releasing hormone analogs .....	240
Traxoprodil .....	240
<b>Biological approaches to neuroprotection in TBI .....</b>	<b>241</b>
Antisense approaches to TBI .....	241
Cell therapy for TBI.....	241
Gene therapy for TBI.....	241
Vaccines for TBI.....	242
<b>Non-pharmaceutical approaches to neuroprotection in TBI .....</b>	<b>242</b>
Deep brain stimulation for TBI.....	242
Hyperbaric oxygen therapy for TBI.....	242
Hypothermia .....	243
Reduction of microglial migration after TBI.....	243
Vacuum for mechanical tissue resuscitation in TBI .....	243
<b>Prophylactic neuroprotection against TBI.....</b>	<b>243</b>
Role of helmets in protection against TBI .....	244
Role of physical exercise in protection against TBI .....	244
<b>Neuroprotection against late sequelae of TBI.....</b>	<b>244</b>
Antiepileptic drugs for prevention of seizures and neuroprotection .....	244
<b>Neuroprotection during rehabilitation phase of TBI.....</b>	<b>245</b>
Neuroregeneration following TBI .....	245
<i>Intrinsic factors that influence regeneration following TBI .....</i>	<i>245</i>
<i>Causes of lack of regeneration following TBI.....</i>	<i>246</i>
<i>Approaches to regeneration of the brain following TBI .....</i>	<i>246</i>
<b>Clinical trials of neuroprotective agents in TBI .....</b>	<b>247</b>
Ongoing clinical trials in TBI .....	247
Failed clinical trials in TBI.....	248
<i>Differences between clinical trials and studies in animal models of TBI .....</i>	<i>249</i>
<i>Subgroup analysis.....</i>	<i>250</i>
<i>Improving the clinical trial design.....</i>	<i>250</i>
<i>Clinical trials combining multiple treatment strategies .....</i>	<i>250</i>
<i>Shortening the trial time.....</i>	<i>250</i>
<b>Conclusions and future prospects of neuroprotection in TBI.....</b>	<b>251</b>
<b>5. Neuroprotection in Spinal Cord Injury .....</b>	<b>252</b>
<b>Introduction .....</b>	<b>252</b>
<b>Pathophysiology of SCI.....</b>	<b>252</b>

<i>Secondary mechanisms of SCI</i> .....	253
<i>Neurotrophic factor changes in SCI</i> .....	254
<b>Management of SCI</b> .....	<b>255</b>
<b>Pharmacological neuroprotective agents for SCI</b> .....	<b>256</b>
4-aminopyridine .....	256
Antibodies as neurite growth inhibitors in SCI.....	256
Antiexcitotoxic agents .....	256
<i>Gacyclidine</i> .....	256
<i>GM-1 ganglioside</i> .....	257
Bacterial enzyme chondroitinase ABC .....	257
Docosahexaenoic acid as neuroprotective in SCI .....	257
Erythropoietin as a neuroprotective in SCI .....	258
Free radical scavengers for neuroprotection in SCI .....	258
GYKI 52466 .....	258
Immunosuppressants as neuroprotectants in SCI.....	258
Interleukin-10 for neuroprotection in SCI.....	259
Matrix metalloproteinase inhibitors for SCI .....	259
Methylprednisolone .....	259
Minocycline as neuroprotective in SCI.....	260
Modulation of macrophage responses for neuroprotection after SCI.....	260
Neurotrophic factors for neuroprotection after SCI .....	261
<i>Promotion of regeneration of neurons in SCI</i> .....	261
Rho pathway and Rho antagonists in SCI .....	262
Selenium as a neuroprotective for SCI.....	262
Sialidase for enhancing recovery after SCI .....	262
Targeting the inflammatory response for neuroprotection in SCI .....	263
Uric acid as neuroprotective in SCI.....	263
<b>Non-pharmacological approaches to SCI</b> .....	<b>263</b>
Hyperbaric oxygen therapy .....	263
Hypothermia for SCI .....	263
<b>Cell therapy for SCI</b> .....	<b>264</b>
Autoimmune T cells against CNS myelin-associated peptide .....	264
Fetal neural grafts for SCI .....	264
Olfactory-ensheathing cells for SCI .....	264
Oligodendrocyte precursor cells for treatment of SCI .....	265
Schwann cell transplants for SCI.....	265
Transplantation of glial cells for SCI .....	265
Stem cells for SCI .....	265
<i>Bone marrow stem cells for SCI</i> .....	266
<i>Embryonic stem cells for SCI</i> .....	266
<i>Transplantation of induced pluripotent stem cells in SCI</i> .....	266
<i>Transplantation of MSCs for SCI</i> .....	267
<i>Transplantation of NSCs for SCI</i> .....	267
<i>Transdifferentiation of stem cells into cholinergic neurons for SCI</i> .....	268
<b>Gene therapy for SCI</b> .....	<b>268</b>
<b>Combined approaches to spinal cord injury</b> .....	<b>269</b>
<b>Discovery of new targets for neuroprotective therapies in SCI</b> .....	<b>270</b>
<b>Clinical trials in SCI</b> .....	<b>270</b>

<b>6. Neuroprotection in Neurodegenerative Disorders</b> .....	<b>272</b>
<b>Introduction</b> .....	<b>272</b>
<b>Pathomechanism of neurodegeneration</b> .....	<b>272</b>
Aging and neurodegeneration .....	272
$\alpha$ -synuclein in neurodegeneration and neuroprotection .....	273
Dysregulation of cyclin-dependent kinase 5 .....	273
Exosomes in CNS neurodegeneration and neuroregeneration.....	273
Genomics of neurodegenerative diseases .....	274
Impairment of neural transport in neurodegenerative disorders .....	274
Lack of neurotrophic factors .....	274
Neuroinflammation in neurodegenerative disorders .....	275
Neurodegeneration associated with protein misfolding .....	275
<i>Modulation of neurodegeneration by molecular chaperones</i> .....	275
<i>Intrabodies targeting protein misfolding in neurodegeneration</i> .....	276
<i>Targeting proteins aggregation to prevent amyloid formation</i> .....	276
<i>Tau and neurodegeneration</i> .....	276
Role of apoptosis in neurodegenerative disorders .....	277
Role of glia in neurodegeneration.....	277
Role of metals in neurodegeneration .....	277
Spread of neurodegeneration .....	278
TDP-43 proteinopathy and neurodegenerative diseases .....	278
Viral infections and neurodegeneration .....	278

<i>AIDS and the nervous system</i> .....	278
<i>Avian influenza as cause of neurodegeneration</i> .....	279
<b>Neurodegenerative disorders with dementia</b> .....	<b>280</b>
Dementia with Lewy bodies .....	280
Frontotemporal dementia .....	281
Progressive supranuclear palsy .....	282
<b>Genetic disorders with neurodegeneration</b> .....	<b>282</b>
Batten disease .....	282
<i>Cell and gene therapies</i> .....	282
<i>Cerliponase alfa</i> .....	283
Familial dysautonomia .....	284
Friedrich ataxia .....	284
<i>Pathomechanism of FA</i> .....	284
<i>Neuroprotection in FA</i> .....	284
Leigh syndrome .....	285
Niemann-Pick type C disease .....	285
Spinal and bulbar muscular atrophy .....	286
<i>Spinal muscular atrophy</i> .....	286
<b>Creutzfeldt-Jakob disease</b> .....	<b>288</b>
Neuroprotection in Creutzfeldt-Jakob disease .....	288
<i>Pharmacological neuroprotectants against CJD</i> .....	289
<i>Innovative approaches to neuroprotection in CJD and future prospects</i> .....	290
<b>Approaches to neuroprotection in neurodegenerative disorders</b> .....	<b>290</b>
Glutamate-based therapies for neurodegenerative disorders .....	290
Histone deacetylase inhibitors for neurodegenerative disorders .....	291
Iron chelation for neuroprotection .....	291
Mitochondria permeability transition pore complex and neuroprotection .....	291
Modulation of proteostasis in neurodegenerative disorders .....	292
<b>7. Neuroprotection in Parkinson Disease</b> .....	<b>294</b>
<b>Introduction</b> .....	<b>294</b>
<b>Epidemiology of Parkinson's disease</b> .....	<b>294</b>
<b>Pathophysiology of Parkinson's disease</b> .....	<b>294</b>
Alteration of dopamine homeostasis .....	295
Apoptosis .....	295
Asynchronous neuronal activity .....	295
Calcium interaction with $\alpha$ -synuclein .....	296
Disruption of iron homeostasis .....	296
Excitotoxicity .....	296
Genetic factors in PD .....	296
Oxidative stress .....	297
Role of neurotrophic factors .....	298
Role of misfolding proteins .....	298
Role of $\alpha$ -synuclein in dementia of PD .....	299
Synaptic vesicle glycoprotein 2C disruption in PD .....	299
<b>Neuroprotective strategies for PD based on pathomechanism</b> .....	<b>299</b>
A genetic animal model of PD for testing neuroprotective strategies .....	300
Aldehyde dehydrogenase 1 protects nigrostriatal dopaminergic neurons .....	301
RNAi screening to identify neuroprotective genes in a PD model .....	301
Strategies to stop aggregation of $\alpha$ -synuclein .....	301
<b>Management of Parkinson's disease</b> .....	<b>302</b>
Limitation of conventionally administered dopamine therapy .....	303
<b>Neuroprotective therapy in PD</b> .....	<b>304</b>
<b>Neuroprotective effect of currently used drugs for PD</b> .....	<b>304</b>
Pramipexole .....	304
Rasagiline mesylate .....	305
Ropinirole .....	306
Rivastigmine for treatment of dementia and falls associated with PD .....	306
Selegiline .....	306
<b>Non-pharmacological strategies for neuroprotection in PD</b> .....	<b>307</b>
Deep brain stimulation for PD .....	307
Effect of exercise and environmental enrichment on PD .....	308
Low-calorie diet in PD .....	308
<b>Development of neuroprotective therapies for PD</b> .....	<b>308</b>
2B3-201 for targeted delivery of methylprednisolone .....	309
9-methyl- $\beta$ -carboline .....	309
Adenosine A <sub>2</sub> receptor antagonists .....	309
Antiapoptotic strategies for PD .....	310
ATP13A2 activation .....	310
Augmenting CNS glucocerebrosidase activity .....	310
$\beta$ 2-Adrenoreceptor agonists .....	311

Calcium channel blockers for PD .....	311
Cell therapies for PD.....	311
<i>Stem cells for PD</i> .....	311
<i>Activation of endogenous stem cells and neural precursors</i> .....	312
Cogane.....	313
Creatine and minocycline .....	313
Conserved dopamine neurotrophic factor for PD.....	313
Doxycycline as a neuroprotectant in PD.....	314
Free radical scavengers for neuroprotection in Parkinson's disease.....	314
<i>Antioxidants</i> .....	314
<i>Diapocynin</i> .....	314
<i>Tea extracts as neuroprotectives</i> .....	315
Gene therapy for PD.....	315
<i>Implantation of genetically engineered cells</i> .....	316
<i>Gene therapy using GDNF and neurturin</i> .....	316
<i>Glutamic acid decarboxylase gene therapy</i> .....	317
<i>Parkin gene therapy</i> .....	317
<i>Concluding remarks about gene therapy for PD</i> .....	318
Heat shock protein 70 .....	318
Liver X receptor $\beta$ agonists.....	318
Melatonin as a neuroprotectant in PD .....	319
Nicotine as a neuroprotective in PD .....	319
Nilotinib for PD .....	319
Neuroprotective effect of leucine-rich repeat kinase-2 inhibitors .....	320
Neuroprotective effect of DJ-1 protein .....	320
Neurotrophic factors.....	320
<i>Basic fibroblast growth factor for PD</i> .....	321
<i>BDNF for PD</i> .....	321
<i>GDNF for PD</i> .....	321
<i>MANF for PD</i> .....	322
<i>Neurturin for PD</i> .....	322
<i>Platelet derived growth factor</i> .....	322
<i>Clinical trials with NTFs</i> .....	323
Nrf2-mediated neuroprotection in PD.....	323
Nuclear receptor-related 1:Retinoid X receptor $\alpha$ activation.....	323
Omega-3 polyunsaturated fatty acids .....	323
RAB3B overexpression.....	324
RNAi therapy for PD .....	324
Safinamide.....	324
Sirtuin 2 inhibitors for neuroprotection in PD .....	325
Squalamine and PD .....	325
Statins and PD.....	326
Targeting Bax.....	326
Vitamin D for neuroprotection in PD .....	326
Vaccine for PD .....	327
<b>Clinical trials of neuroprotection in Parkinson's disease .....</b>	<b>327</b>
<b>Evaluation of neuroprotective therapies for PD .....</b>	<b>329</b>
<b>Current status and future challenges for neuroprotection in PD .....</b>	<b>330</b>
<b>8. Neuroprotection in Alzheimer Disease .....</b>	<b>332</b>
<b>Introduction .....</b>	<b>332</b>
<b>Pathomechanism of Alzheimer's disease .....</b>	<b>332</b>
Role of glutamate transport dysfunction in AD .....	333
Role of neurotrophic factors in the pathomechanism of AD .....	333
<b>Management of Alzheimer's disease .....</b>	<b>333</b>
<b>Neuroprotection in Alzheimer's disease .....</b>	<b>334</b>
<b>Inhibition of A<math>\beta</math> formation and aggregation.....</b>	<b>335</b>
AN-1792 .....	335
Clioquinol.....	336
Colostrinin .....	336
FKBP52 for neuroprotection from Cu toxicity in AD.....	337
Monoclonal antibody m266.....	337
Phenserine.....	337
Secretase inhibitors.....	338
<b>Inhibition of neuroinflammation.....</b>	<b>338</b>
Etanercept .....	338
<b>Neurotrophic factors for neuroprotection in AD .....</b>	<b>339</b>
AL-108 .....	339
NGF gene therapy .....	339
Small molecule compounds binding to neurotrophin receptor p75NTR.....	340
Targeting plasminogen activator inhibitor type-1 gene.....	341

<b>Estrogen and AD</b> .....	<b>341</b>
<b>Antioxidants</b> .....	<b>342</b>
NSAIDS .....	342
<b>Melatonin for AD</b> .....	<b>342</b>
<b>Memantine</b> .....	<b>342</b>
<b>Dimebon</b> .....	<b>343</b>
<b>Cerebrolysin</b> .....	<b>344</b>
<b>Curcumin as a neuroprotectant in Alzheimer disease</b> .....	<b>344</b>
<b>Ginko biloba</b> .....	<b>344</b>
<b>Tetrahydrocannabinol for neuroprotection in AD</b> .....	<b>345</b>
<b>Ladostigil tartrate</b> .....	<b>346</b>
<b>Phosphodiesterase inhibitors as neuroprotectives</b> .....	<b>346</b>
<b>PPAR-γ agonists</b> .....	<b>346</b>
<b>Role of statins in reducing the risk of AD</b> .....	<b>347</b>
<b>Combined therapeutic approaches to AD</b> .....	<b>347</b>
<b>Clinical trials in AD</b> .....	<b>347</b>
<b>Future prospects of neuroprotection in AD</b> .....	<b>356</b>
<b>Mild cognitive impairment</b> .....	<b>356</b>
Relation of MCI to AD .....	357
Neuroprotection in MCI .....	357
<i>Pharmacological approaches for MCI</i> .....	357
<i>Non-pharmacological approaches to MCI</i> .....	358
<b>9. Neuroprotection in Huntington Disease</b> .....	<b>360</b>
<b>Introduction</b> .....	<b>360</b>
<b>Pathophysiology of HD</b> .....	<b>360</b>
<b>Management of Huntington's disease</b> .....	<b>362</b>
<b>Neuroprotection in Huntington's disease</b> .....	<b>362</b>
Antipsychotic D <sub>2</sub> and 5-HT <sub>1A</sub> antagonists .....	363
Caspase inhibitors.....	363
Clioquinol for HD.....	364
Creatine for stabilizing bioenergetic defects.....	364
Cysteine and neuroprotection in HD .....	364
<i>Cysteine metabolism reprogramming for neuroprotection in HD</i> .....	364
<i>Cysteamine</i> .....	364
Drugs that block inappropriate calcium release from neurons .....	365
Enhancing protease activity for clearance of mHtt .....	365
Eicosapentaenoic acid.....	365
Free radical scavengers .....	366
Histone deacetylase inhibitors .....	366
Inhibitors of polyglutamine aggregation HD.....	366
Metal-protein attenuating compounds.....	367
Pridopidine.....	367
RRAS signaling pathway inhibition.....	367
Simvastatin as a neuroprotective in HD .....	368
Single chain Fv antibodies.....	368
SIRT1 activators for neuroprotection in HD .....	368
SIRT2 inhibitors for neuroprotection in HD .....	369
Synaptic activation of NMDA receptors.....	369
Targeting mutant huntingtin protein.....	369
Tetrabenazine .....	370
Combinatorial therapy and targeting multiple pathways in HD .....	370
Cell therapy for HD .....	371
<i>Cell transplants for HD</i> .....	371
<i>Stem cell-based therapy for HD</i> .....	371
Neurotrophic factors and gene therapy .....	372
RNAi and antisense therapies for Huntington's disease .....	373
<b>10. Neuroprotection in Amyotrophic Lateral Sclerosis</b> .....	<b>376</b>
<b>Introduction</b> .....	<b>376</b>
<b>Pathophysiology of ALS</b> .....	<b>376</b>
<b>Neuroprotective therapies for ALS</b> .....	<b>381</b>
Activated protein C .....	382
AEOL 10150 .....	382
AIMSPRO .....	382
Anakinra.....	383
Antisense therapy .....	383
Arimoclomol for ALS.....	383
Ceftriaxone for ALS .....	384
Coenzyme Q10 for ALS .....	384
COX-2 inhibitors for ALS .....	384

Creatine for ALS .....	385
Dexpramipexole.....	385
Diallyl trisulfide.....	386
Edaravone for ALS .....	386
Erythropoietin for ALS .....	386
Gene therapy for ALS .....	386
Glatiramer acetate .....	387
GM602 .....	387
Insulin-like growth factor .....	387
Ketogenic diet for neuroprotection in ALS.....	388
Lenalidomide.....	388
Lithium for neuroprotection in ALS .....	389
Masitinib .....	389
Melatonin for ALS.....	389
Methylcobalamin.....	390
Minocycline for ALS .....	390
Olesoxime as neuroprotective for ALS.....	390
ONO-2506 for ALS .....	390
Riluzole .....	391
RNAi-based therapy for ALS .....	391
Sodium phenylbutyrate.....	391
Stem cell therapy.....	392
<i>Clinical applications</i> .....	392
<i>Stem cell-based drug discovery for ALS</i> .....	392
<i>Suppressors of mTDP-43 toxicity</i> .....	393
Talampanel .....	393
Tamoxifen.....	394
Vaccination for ALS caused by SOD1 mutations .....	394
Vascular endothelial growth factor for ALS .....	394
Vitamin E for ALS.....	395
<b>Clinical trials of neuroprotective therapies for ALS .....</b>	<b>395</b>
<b>Concluding remarks and future prospects.....</b>	<b>398</b>
Use of CRISPR/Cas9 technology to find new targets in ALS .....	398

<b>11. Neuroprotection in Miscellaneous Neurological Disorders .....</b>	<b>400</b>
<b>Introduction .....</b>	<b>400</b>
<b>Neuroprotection in synaptopathies.....</b>	<b>400</b>
Neuroprotection in ASD .....	401
Neuroprotection in fragile X syndrome.....	401
<b>Neuroprotection in dementia .....</b>	<b>401</b>
Age-related dementia .....	401
<i>Aging brain and oxidative stress</i> .....	402
<i>Enhancing endogenous neurotrophic support of the aging brain</i> .....	402
<i>Hsp70 and age-related neurodegeneration</i> .....	403
<i>Pharmacological approaches for treatment of age-related dementia</i> .....	403
<i>Physical exercise to prevent decline of mental function with aging</i> .....	404
Vascular dementia .....	404
<i>Prediction of dementia in persons with vascular risk factors</i> .....	405
<i>Management of subcortical vascular dementia</i> .....	405
Dementia with Lewy bodies.....	406
Neuroprotection in AIDS dementia .....	406
<b>Multiple system atrophy .....</b>	<b>407</b>
<b>Epilepsy .....</b>	<b>408</b>
Mechanisms of neuronal damage in epilepsy .....	408
Strategies for neuroprotection in epilepsy .....	409
AEDs and neuroprotection.....	409
Cell therapy for neuroprotection in epilepsy.....	410
<i>Cell therapy of posttraumatic epilepsy</i> .....	411
<i>Cell therapy for temporal lobe epilepsy</i> .....	411
<i>Cell therapy for pharmacoresistant epilepsies</i> .....	412
Drugs targeting mossy cells in drug-resistant epilepsy.....	412
Gene therapy for neuroprotection in epilepsy .....	412
Hyaluronan-based preservation of brain ECS volume.....	413
Hypothermia for neuroprotection in status epilepticus.....	413
Ketogenic diet for prevention of seizures.....	414
miR-211 as an attenuator of cholinergic-mediated seizures.....	414
<b>Multiple sclerosis .....</b>	<b>414</b>
Introduction .....	414
Epidemiology of multiple sclerosis .....	414
Pathophysiology .....	415
Current management of multiple sclerosis.....	415

Specific therapies for MS based on pathomechanism .....	416
Neuroprotection in multiple sclerosis .....	417
Clinical trials of neuroprotective therapies for MS.....	418
Neuroprotection by control of progressive forms of multiple sclerosis .....	419
Neuroprotection by controlling autoimmune inflammation in the brain.....	419
Neuroprotection by sealing the BBB with imatinib .....	420
TRPM4 cation channel blockers .....	420
Remyelination for neuroprotection in multiple sclerosis.....	420
Agents for neuroprotection in multiple sclerosis .....	421
<i>Angiotensin-II inhibitors</i> .....	421
<i>Antiglutamate agents</i> .....	421
<i>Antioxidants for neuroprotection in MS</i> .....	421
<i>Antisense and RNAi approaches to MS</i> .....	422
<i>B cell depletion therapy</i> .....	422
<i>Cell therapy for multiple sclerosis</i> .....	422
<i>Cannabinoids for neuroprotection in MS</i> .....	425
<i>Cladribine</i> .....	426
<i>Curcumin as a neuroprotectant in multiple sclerosis</i> .....	426
<i>Cytokine-directed therapies in MS</i> .....	426
<i>Dalfampridine in MS</i> .....	427
<i>Dimethyl fumarate</i> .....	427
<i>DNA vaccine for MS</i> .....	427
<i>Erythropoietin as a neuroprotective in MS</i> .....	428
<i>Fingolimod</i> .....	428
<i>Fusokine composed of GM-CSF and IL-15 for immune suppression</i> .....	429
<i>Gene therapy for MS</i> .....	429
<i>Ibudilast for MS</i> .....	429
<i>Iron chelators</i> .....	430
<i>IVIG for MS</i> .....	430
<i>Kinase inhibitors</i> .....	430
<i>Laquinimod</i> .....	430
<i>Melatonin for MS</i> .....	431
<i>Minocycline for MS</i> .....	431
<i>Monoclonal antibodies for MS</i> .....	431
<i>Natalizumab</i> .....	432
<i>Natural human antibodies for repair of myelin</i> .....	433
<i>Neurotrophic factors for multiple sclerosis</i> .....	433
<i>Nimodipine</i> .....	434
<i>Oral immunomodulatory agents for MS</i> .....	434
<i>Protein kinase C<math>\beta</math> as a therapeutic target for stabilizing BBB in MS</i> .....	435
<i>Recombinant T-cell ligands</i> .....	435
<i>Statins for MS</i> .....	435
<i>Teriflunomide</i> .....	436
<i>Tolerance-directed immunotherapy for MS</i> .....	436
Concluding remarks and future prospects for neuroprotection in MS .....	436
<b>Neuroprotection in anti-NMDA receptor encephalitis .....</b>	<b>437</b>
<b>Neuroprotection in transverse myelitis.....</b>	<b>438</b>
<b>Neuroprotection in decompression sickness .....</b>	<b>438</b>
<b>Neuroprotection in victims of drowning .....</b>	<b>439</b>
<b>Neuroprotection in CSF circulatory disorders.....</b>	<b>439</b>
Neuroprotection in hydrocephalus .....	440
Neuroprotection in normal pressure hydrocephalus .....	440
<b>Neuroprotection in infections of the CNS .....</b>	<b>441</b>
Neuroprotection in bacterial meningitis .....	441
<i>Mechanism of neural injury in bacterial meningitis</i> .....	441
<i>Strategies for neuroprotection</i> .....	442
Neuroprotection in cryptococcal meningitis.....	442
Neuroprotective approach to rabies.....	442
Neuroprotection in cerebral malaria.....	443
<b>Neuroprotection in complications of systemic disorders .....</b>	<b>443</b>
Neurological complications of cardiovascular disorders.....	443
<i>Neuroprotection after myocardial infarction</i> .....	443
<i>Neuroprotection in hypertensive encephalopathy</i> .....	444
<i>Management of hypertension to prevent dementia</i> .....	444
Neuroprotection in complications of diabetes .....	444
<i>Neuroprotection in hypoglycemic coma</i> .....	444
<i>Neuroprotection in diabetic retinopathy</i> .....	445
Neurological complications of liver disorders.....	446
<i>Hepatic encephalopathy</i> .....	446
<i>Bilirubin encephalopathy</i> .....	447
Neuroprotection in neurological complications of renal disease. ....	448



Neuroprotection in fever .....	448
<i>Pharmacologic approaches for fever</i> .....	450
<i>Cooling the brain for neuroprotection</i> .....	451
<b>Neuroprotection in toxic encephalopathies.....</b>	<b>451</b>
Encephalopathy due to organophosphorus poisoning .....	451
Neuroprotection against chemotherapy-induced brain damage .....	452
Neuroprotection against alcohol .....	452
<i>Alcoholic neurologic disorders</i> .....	452
<i>Fetal alcohol syndrome</i> .....	453
<i>Pathogenesis of alcohol-induced damage to the nervous system</i> .....	453
<i>Neuroprotection against neurotoxicity of alcohol</i> .....	453
<b>Neuroprotection against exposure to therapeutic radiation.....</b>	<b>454</b>
Neuroprotection against radiation encephalopathy .....	454
Role of SOD in protection again radiation-induced hippocampal dysfunction .....	454
Catalase reduces mitochondrial ROS for neuroprotection from proton irradiation.....	455
<b>Neuroprotection in hypoxia-ischemia .....</b>	<b>455</b>
<b>Neuroprotection of the fetus and the neonate .....</b>	<b>455</b>
Neuroprotection in preterm babies .....	456
Neuroprotection in neonatal hypoxic-ischemic brain injury .....	456
<i>Pathomechanism of neonatal hypoxic-ischemic brain injury</i> .....	456
<i>Management of neonatal hypoxia-ischemia</i> .....	457
<i>Approaches to neuroprotection in neonatal hypoxia-ischemia</i> .....	457
<i>Hyperbaric oxygen for neonatal hypoxia-ischemia</i> .....	458
<i>Hyperthermia for neonatal hypoxia-ischemia</i> .....	458
<i>Melatonin for neonatal hypoxia-ischemia</i> .....	458
<i>Minocycline for neonatal hypoxia-ischemia</i> .....	458
<i>Nicotinamide mononucleotide adenylyl transferase 1</i> .....	459
<i>Nitric oxide inhalation for neonatal hypoxia-ischemia</i> .....	459
<i>Plasminogen activator inhibitor-1 for neonatal hypoxia-ischemia</i> .....	459
<i>Recombinant erythropoietin for neonatal hypoxia-ischemia</i> .....	459
<b>Neuroprotection in carbon monoxide poisoning.....</b>	<b>460</b>
Pathomechanism of CO poisoning as a basis for neuroprotection.....	460
Management of CO poisoning .....	461
<b>Neuroprotection after cardiac arrest.....</b>	<b>461</b>
<b>Neuroprotection in delayed post-hypoxic leukoencephalopathy .....</b>	<b>462</b>
<b>Neuroprotection in sleep apnea .....</b>	<b>462</b>
<b>Neuroprotection in mitochondrial dysfunction.....</b>	<b>463</b>
Mitochondrial permeability transition .....	463
Mitochondrial approaches for neuroprotection.....	464
Methylene blue .....	465
Role of nanolasers in evaluation of mitochondrial neuroprotectants .....	465
Neuroprotection in mitochondrial encephalopathies .....	465
<b>Neuroprotection in psychiatric disorders .....</b>	<b>466</b>
Cognitive impairment in schizophrenia.....	466
Electroconvulsive therapy and neuroprotection .....	466
Neuroprotection in schizophrenia .....	467
Neuroplasticity and neuroprotection in stress-induced psychiatric disorders.....	467
<b>Neuroprotection in hearing loss.....</b>	<b>467</b>
Causes of hearing loss .....	468
Pathomechanism of hearing loss .....	468
Prevention and treatment of hearing loss.....	469
<i>Hyperbaric oxygen for hearing loss</i> .....	469
<i>Stem cell therapy for hearing loss</i> .....	469
<i>Auditory hair cell replacement by gene therapy</i> .....	470
<i>Pharmaceutical approaches to hearing loss</i> .....	470
<b>Neuroprotection of peripheral nerves .....</b>	<b>472</b>
Neuroprotective agents for peripheral nerves .....	472
<i>Acetyl-L-carnitine for peripheral nerve injuries</i> .....	472
<i>Atorvastatin for peripheral nerve injuries</i> .....	472
<i>Erythropoietin for neuroprotection in peripheral nerve injuries</i> .....	473
Neuroprotection in peripheral nerve injuries .....	473
<i>Role of hyperbaric oxygen in peripheral nerve injuries</i> .....	473
<i>Role of neurotrophic factors in peripheral nerve injuries</i> .....	474
<i>Pharmacological approaches to Schwann cells</i> .....	474
<i>Role of gene therapy in neuroprotection of injured peripheral nerves</i> .....	474
<i>Schwann cell transplantation for peripheral nerve injury</i> .....	474
<i>Targeting Wallerian degeneration slow protein for neuroprotection</i> .....	475
Peripheral neuropathy .....	475
<i>Neuroprotection in diabetic neuropathy</i> .....	475
<i>Cell therapy for neuroprotection in diabetic neuropathy</i> .....	476
<i>Gene therapy with zinc finger DNA-binding proteins</i> .....	476

<i>Neuroprotection in chemotherapy-induced neuropathy</i> .....	476
Chronic inflammatory demyelinating polyradiculoneuropathy .....	477
<i>Neuroprotection in CIDP</i> .....	477
<b>12. Neuroprotection of the Optic nerve and the Retina .....</b>	<b>478</b>
<b>Introduction .....</b>	<b>478</b>
<b>Optic neuropathy .....</b>	<b>478</b>
Pathophysiology .....	478
Neuroprotection in optic neuritis .....	479
<i>Evaluating efficacy of drugs for optic neuritis</i> .....	480
<i>Flupirtine</i> .....	480
<i>Sodium channel blockers</i> .....	481
<i>Resveratrol</i> .....	481
<b>Neuroprotection in optic nerve trauma .....</b>	<b>481</b>
Potential regeneration of the optic nerve .....	482
Subthreshold transpupillary thermotherapy for protection of RGCs .....	482
<b>Neuroprotection of optic nerve in glaucoma .....</b>	<b>482</b>
Aminoguanidine as a neuroprotective in glaucoma .....	484
Antiglutamate agents for neuroprotection of optic nerve .....	484
Betaxolol .....	484
NGF eye drops .....	484
Targeting A $\beta$ in glaucoma treatment .....	485
TNF- $\alpha$ blockers for neuroprotection in glaucoma .....	485
Concluding remarks about neuroprotection in glaucoma .....	485
<b>Neuroprotection in retinal ischemia .....</b>	<b>485</b>
$\beta$ -adrenoceptor antagonists .....	486
Brimonidine as a neuroprotective in ischemic retinopathy .....	486
Endogenous neuroprotection in the retina .....	487
Erythropoietin for neuroprotection of retinal ischemia .....	487
Gene therapy for retinal neuroprotection .....	487
Hyperbaric oxygen for central retinal artery occlusion .....	488
Levodopa for treating non-arteritic anterior ischemic optic neuropathy .....	488
Thioredoxin as a neuroprotective agent in retinal ischemia .....	488
<b>Protection against oxygen-induced retinopathy .....</b>	<b>488</b>
<b>Neuroprotection in macular degeneration .....</b>	<b>489</b>
Epidemiology .....	489
Pathomechanism of AMD .....	489
Current treatment of AMD .....	489
Novel neuroprotective strategies against retinal degeneration .....	491
Antiangiogenic agents .....	492
Humanized MAb against A $\beta$ .....	492
LXR agonists .....	493
Neurotrophic factors for neuroprotection in AMD .....	493
<i>CNTF for neuroprotection in AMD</i> .....	493
<i>N-acetylserotonin derivatives</i> .....	493
Nutritional protection against AMD .....	493
Progestogenic hormones .....	494
Protection of retinal cells from oxidative-stress-induced apoptosis .....	494
Sulindac .....	494
Tandospirone .....	495
Cell therapy for macular degeneration .....	495
<i>Retinal pigment epithelial cells</i> .....	495
<i>Stem cells</i> .....	495
<i>Neural progenitor cells</i> .....	495
Gene therapy for retinal degeneration .....	496
RNAi-based treatments for AMD .....	496
<b>Neuroprotection in proliferative diabetic retinopathy .....</b>	<b>497</b>
RNAi-based approaches to diabetic retinopathy .....	497
<b>Clinical trials for optic nerve and retinal neuroprotection .....</b>	<b>498</b>
<b>13. Neuroprotection during Anesthesia and Surgery .....</b>	<b>500</b>
<b>Introduction .....</b>	<b>500</b>
<b>Anesthetic agents as neuroprotectives .....</b>	<b>500</b>
Barbiturates .....	500
<i>Thiopental</i> .....	501
Etomidate .....	502
Propofol .....	502
Ketamine .....	502
Gaseous anesthetics .....	503
<i>Isoflurane</i> .....	503
<i>Xenon</i> .....	503

Local anesthetics .....	504
<b>Monitoring of CNS function during anesthesia and surgery .....</b>	<b>504</b>
Monitoring of cerebral function .....	504
Monitoring of spinal cord function during spinal surgery .....	504
<b>Perioperative neuroprotection .....</b>	<b>505</b>
<b>Neuroprotection during cardiovascular procedures .....</b>	<b>506</b>
CNS complications of cardiac surgery .....	506
Neuroprotective strategies during cardiac surgery .....	507
<i>Neuroprotection before anticipated or induced cardiac arrest.....</i>	<i>508</i>
<i>Neuroprotection during coronary artery bypass grafting.....</i>	<i>508</i>
<i>Preconditioning with hyperbaric oxygen.....</i>	<i>509</i>
<i>Neuroprotection in aortic surgery.....</i>	<i>509</i>
<i>Pharmacologic strategies for neuroprotection in aortic surgery.....</i>	<i>510</i>
<b>Cerebral protection during organ transplantation surgery.....</b>	<b>510</b>
<b>Cerebral protection during neurosurgery .....</b>	<b>511</b>
Cerebral angiography and endovascular surgery .....	511
Cerebral protection during surgery for arteriovenous malformations .....	511
Cerebral protection during surgery of intracranial aneurysms .....	511
Management of subarachnoid hemorrhage .....	512
<i>Vasospasm associated with subarachnoid hemorrhage.....</i>	<i>512</i>
Cerebral protection during carotid endarterectomy.....	514
Cerebral protection during surgery of brain tumors .....	514
Neuroprotective measures prior to surgery.....	515
<i>HBO preconditioning for neuroprotection during surgery .....</i>	<i>515</i>
Neuroprotection following surgery.....	515
<i>Neuroprotection by cranioplasty after decompressive craniectomy .....</i>	<i>516</i>
<b>14. Markets for Neuroprotective Therapies.....</b>	<b>518</b>
<b>Introduction .....</b>	<b>518</b>
<b>The financial burden of CNS damage .....</b>	<b>518</b>
<b>Markets for neuroprotective therapies.....</b>	<b>518</b>
Markets according to therapeutic areas.....	518
<i>Stroke .....</i>	<i>519</i>
<i>CNS injury .....</i>	<i>519</i>
<i>Alzheimer disease .....</i>	<i>520</i>
<i>Parkinson disease .....</i>	<i>520</i>
<i>Multiple sclerosis.....</i>	<i>520</i>
<i>Epilepsy.....</i>	<i>520</i>
Values of neuroprotective therapies in major world markets.....	520
Unmet needs in neuroprotectives.....	521
<b>Future of neuroprotective therapies .....</b>	<b>522</b>
Challenges in neuroprotective drug development .....	522
Promising areas of research in neuroprotection.....	523
<i>Autoreactive antibodies .....</i>	<i>523</i>
<i>Biological therapies for neuroprotection .....</i>	<i>523</i>
<i>Multidisciplinary approaches to neuroprotection .....</i>	<i>524</i>
<b>15. References.....</b>	<b>526</b>

## Tables

Table 1-1: Historical landmarks in the development of neuroprotection .....	32
Table 1-2: Intrinsic neuroprotective factors.....	37
Table 1-3: Common features of pathophysiology of brain damage in diseases .....	45
Table 1-4: Place of neuroprotection in management of CNS disorders .....	47
Table 1-5: Indications for the use of neuroprotection .....	47
Table 1-6: Neuroprotective nanoparticles.....	53
Table 2-1: A classification of neuroprotective agents .....	56
Table 2-2: The neuroprotective effect of antiepileptic drugs .....	65
Table 2-3: Neuroprotective affect of minocycline in animal models.....	70
Table 2-4: Classification of antioxidants or free radical scavengers with neuroprotective potential.....	78
Table 2-5: Role of erythropoietin in the nervous system .....	83
Table 2-6: Ionotropic glutamate receptors .....	89
Table 2-7: Classification of metabotropic glutamate receptors (mGluRs) .....	89
Table 2-8: Methods for neuroprotection based on nonpharmacological preconditioning .....	141
Table 3-1: Cerebrovascular diseases that are relevant to neuroprotection.....	146
Table 3-2: Neuroprotective strategies for stroke .....	157
Table 3-3: Selected effective combinations of hypothermia with other neuroprotective strategies for the treatment of ischemic stroke in experimental models .....	188

Table 3-4: Neuroprotective gene transfer in models of cerebral ischemia .....	196
Table 3-5: Neuroprotective gene therapy in animal stroke models .....	196
Table 3-6: Neuroprotective agents in clinical development for acute cerebrovascular disease .....	199
Table 3-7: Some failed trials for neuroprotective therapy for stroke .....	202
Table 3-8: Preclinical assessment of neuroprotective agents in acute stroke models.....	211
Table 3-9: Stroke prevention based on control of risk factors .....	214
Table 4-1: Classification of closed TBI .....	216
Table 4-2: Current conventional management of traumatic brain injury .....	225
Table 4-3: Neuroprotective strategies for traumatic brain injury .....	227
Table 4-4: Intrinsic factors that influence regeneration in the central nervous system .....	245
Table 4-5: A classification of approaches to regeneration of the brain following injury .....	246
Table 4-6: Ongoing or completed clinical trials for neuroprotection in TBI .....	248
Table 4-7: Discontinued or failed clinical trials for neuroprotection in TBI.....	249
Table 5-1: Secondary mechanisms in spinal cord injury .....	254
Table 5-2: Neuroprotective and regenerative approaches for SCI.....	255
Table 5-3: Clinical trials for neuroprotection in SCI .....	270
Table 6-1: Neurodegenerative disorders with dementia .....	280
Table 6-2: Drugs in clinical trials for spinal muscular atrophy .....	287
Table 6-3: Approaches to neuroprotection in CJD.....	288
Table 6-4: Glutamate-based therapies in clinical development for neurodegenerative disorders.....	290
Table 7-1: Prevalence of Parkinson's disease in major markets 2016-2026 .....	294
Table 7-2: Factors in the etiology of Parkinson's disease.....	294
Table 7-3: Strategies for the treatment of Parkinson's disease .....	302
Table 7-4: Gene therapy techniques applicable to Parkinson disease .....	315
Table 7-5: Current clinical trials of neuroprotective therapies for Parkinson disease .....	327
Table 7-6: Failed clinical trials of neuroprotective therapies for Parkinson disease.....	328
Table 7-7: Evaluation of neuroprotective agents for PD .....	329
Table 8-1: Cholinergic approaches to the treatment of Alzheimer's disease .....	334
Table 8-2: Neuroprotective agents for Alzheimer's disease.....	334
Table 8-3: Clinical trials for neuroprotection in Alzheimer disease .....	347
Table 8-4: Discontinued, failed or inconclusive clinical trials of Alzheimer disease .....	353
Table 8-5: Strategies for discovery of neuroprotective therapies for AD .....	356
Table 9-1: Neuroprotective approaches in HD.....	362
Table 10-1: Hypotheses for the pathogenesis of amyotrophic lateral sclerosis .....	376
Table 10-2: Genetic diagnostic biomarkers of ALS.....	379
Table 10-3: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	381
Table 10-4: Clinical trials of neuroprotective therapies for ALS .....	395
Table 10-5: Failed or discontinued trials of neuroprotective therapies for ALS.....	396
Table 11-1: Therapeutic approaches to subcortical vascular dementia .....	405
Table 11-2: Measures for neuroprotection against the sequelae of seizures.....	409
Table 11-3: Neuroprotective effect of AEDs in animal models of status epilepticus (SE) .....	410
Table 11-4: Specific therapies for MS based on postulated pathomechanisms.....	416
Table 11-5: Approved neuroprotective therapies for multiple sclerosis.....	417
Table 11-6: Neuroprotective therapies for multiple sclerosis in clinical trials .....	418
Table 11-7: Measures to prevent acute bilirubin encephalopathy .....	447
Table 11-8: Fever associated with neurologic disorders .....	449
Table 11-9: Approaches to neuroprotection in neonatal hypoxia-ischemia.....	457
Table 11-10: Drugs with neuroprotective effect at mitochondrial level .....	464
Table 11-11: Causes of sensorineural hearing impairment .....	468
Table 11-12: Strategies for prevention and treatment of sensorineural hearing loss.....	469
Table 11-13: Agents for neuroprotection of the peripheral nervous system .....	472
Table 12-1: Causes of optic neuropathy.....	478
Table 12-2: Clinical trials of neuroprotective therapies in optic neuritis.....	480
Table 12-3: Neuroprotection of the optic nerve in glaucoma.....	483
Table 12-4: Strategies for neuroprotection in retinal ischemia .....	486
Table 12-5: Novel neuroprotective strategies against retinal degeneration .....	491
Table 12-6: Clinical trials for retinal neuroprotection .....	498
Table 13-1: CNS complications associated with cardiac procedures .....	506
Table 13-2: Strategies for protection of the brain during cardiac surgery .....	507
Table 13-3: Medical and surgical methods of cerebral vasospasm management.....	513
Table 13-4: Neuroprotection by prevention of vasospasm.....	513
Table 14-1: Neuroprotective market values 2017-2027 .....	519
Table 14-2: Values of neuroprotective therapies in major world markets from 2017-26 .....	520

## Figures

Figure 2-1: Mechanism of neuroprotective effect of sigma-1 receptor agonists .....	64
Figure 2-2: NMDA receptor ion channel complex.....	93
Figure 2-3: Neuroprotective effect of galantamine .....	116
Figure 3-1: Some steps in the ischemic cascade and site of action of neuroprotectives .....	147

Figure 3-2: Relationship between dementia and acute ischemic stroke .....	156
Figure 3-3: Molecules involved in preconditioning for neuroprotection in ischemia.....	190
Figure 3-4: A roadmap for neuroprotection .....	212
Figure 4-1: Cascade of events following traumatic brain injury .....	218
Figure 4-2: Neurometabolic cascade of mild TBI .....	219
Figure 4-3: Secondary injury mechanisms after TBI .....	220
Figure 4-4: Management of raised ICP after TBI .....	226
Figure 5-1: Pathomechanism of acute spinal cord injury .....	253
Figure 7-1: Neuroprotective strategies against death of dopamine-containing neurons in PD .....	300
Figure 9-1: Role of HTT protein in pathogenesis of HD and points of intervention.....	370
Figure 9-2: Antisense therapeutic approaches to HD for lowering huntingtin .....	374
Figure 11-1: A schematic overview of synaptopathies.....	400
Figure 11-2: Common mechanisms of neural damage in cerebral ischemia and seizures .....	408
Figure 11-3: Role of neuroprotection in epilepsy and its treatment.....	409
Figure 11-4: Mechanisms of neonatal hypoxia-ischemia and targets for neuroprotection.....	457
Figure 14-1: Unmet therapeutic needs in neuroprotective therapies .....	522